Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM8QXOC)

Drug Name
Enasidenib Drug Info
Synonyms
Enasidenib; Enasidenib mesylate; IDHIFA; 1446502-11-9; 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol; 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-; 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol; 3T1SS4E7AG; AG-221; CC-90007; CC-90007 Free Base; UNII-3T1SS4E7AG
Cross-matching ID
PubChem CID
89683805
ChEBI ID
CHEMBL145374
CAS Number
CAS 1446502-11-9
INTEDE Drug ID
DR0574

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Fructose and mannose metabolism 2.10 0.00e+0 30/33 (90.91%) AKR1B10;HK2;GMDS;...
Amino sugar and nucleotide sugar metabolism 1.99 7.30e-3 38/48 (79.17%) HK2;GMDS;CHIT1;...
Nitrogen metabolism 1.92 7.30e-3 16/17 (94.12%) CA2;CA9;CA12;...
Starch and sucrose metabolism 1.85 9.12e-3 25/36 (69.44%) ENPP1;HK2;GYG2;...
Non-homologous end-joining 1.77 2.92e-2 11/13 (84.62%) PRKDC;DCLRE1C;DNTT;...
Mucin type O-glycan biosynthesis 1.76 2.43e-2 20/36 (55.56%) GALNT3;GCNT3;GCNT1;...
Folate biosynthesis 1.73 3.44e-2 23/26 (88.46%) AKR1B10;AKR1C3;FPGS;...
Small cell lung cancer -1.70 4.75e-2 90/92 (97.83%) PIK3CA;PIK3CB;LAMA4;...
Antigen processing and presentation -1.71 4.30e-2 60/78 (76.92%) HSPA4;PDIA3;CD4;...
Viral myocarditis -1.72 3.88e-2 53/60 (88.33%) ITGAL;RAC1;HLA-F;...
Graft-versus-host disease -1.75 2.83e-2 32/42 (76.19%) HLA-F;CD86;HLA-B;...
Type I diabetes mellitus -1.76 2.88e-2 38/43 (88.37%) ICA1;HLA-F;CD86;...
Th17 cell differentiation -1.76 2.94e-2 95/107 (88.79%) IL2RB;CD4;NFATC1;...
Basal cell carcinoma -1.76 3.43e-2 41/63 (65.08%) TCF7;GADD45B;FZD2;...
Legionellosis -1.90 9.70e-3 51/57 (89.47%) RAB1A;HSPA1A;CXCL8;...
Rheumatoid arthritis -1.91 9.09e-3 78/93 (83.87%) FOS;ANGPT1;ATP6V0A4;...
ECM-receptor interaction -1.95 8.08e-3 80/88 (90.91%) TNXB;ITGA4;LAMA4;...
Toxoplasmosis -1.95 1.21e-2 103/112 (91.96%) LAMA2;TGFB1;LAMB2;...
Steroid biosynthesis -2.05 0.00e+0 19/20 (95%) EBP;NSDHL;LSS;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H